文章核心观点 - 公司将于2024年11月4日发布第三季度财报 [1] - 公司将于当日下午1:30(太平洋时间)举行财报电话会议 [1][2] 公司概况 - 公司是基因测序和芯片技术的全球领导者,为研究、临床、应用等领域的客户提供产品和服务 [3] - 公司致力于通过基因组学技术来改善人类健康 [3] 财报电话会议 - 电话会议将于2024年11月4日下午4:30(东部时间)开始 [2] - 投资者和分析师可通过公司网站或拨打电话号码参与会议 [2] - 会议结束后,公司将在网站上提供录音回放 [2]

文章核心观点 - Illumina公司过去一年股价上涨25% [1] - 作者拥有30年投资经验,旗下基金过去25年平均年收益率为17%,高于纳斯达克指数11% [1] - 作者持有Illumina公司股票,并撰写本文表达自己的观点 [1] 公司概况 - Illumina是一家生物技术公司,专注于基因测序和相关试剂的研发和生产 [1] - 公司过去一年股价上涨25% [1] 行业分析 - 生物技术行业是一个快速发展的行业,具有较大的投资潜力 [1] - 作者旗下基金过去25年平均年收益率为17%,高于纳斯达克指数11% [1]

In June 2024, GRAIL, Inc. (NASDAQ: GRAL ) was spun-off from Illumina, Inc. ( ILMN ), which had initially acquired GRAIL as recently as 2021. After struggling to defend the merger with regulatory agencies in theI'm Construction Manager for one of America's largest retailers by day, and a stock analyst by night (usually early morning). As a self-taught investor, everything I know about investing came from reading books. Mainly Benjamin Graham, Joel Greenblatt, and Tobias Carlisle, but also countless others.. ...

The market bounced back Monday after a rough week last week. We are not out of the woods yet as a huge CPI report looms on Wednesday. That sort of risk event has the power to rock financial markets. Investors looking for stocks to buy should look outside of the crowded names out there. Yes, there are opportunities outside of the Mag 7. One way to uncover these opportunities is by leaning on the Zacks Rank. Stocks with favorable Zacks Ranks have strong earnings trends which could spell profits in the future. ...

MIAMI, Sept. 9, 2024 /PRNewswire/ -- The FDA has granted approval on Illumina's TruSight Oncology Comprehensive Assay, marking a transformative milestone in cancer diagnostics. This innovative in vitro diagnostic (IVD) kit is the first of its kind, offering distributable comprehensive genomic profiling (CGP) with pan-cancer companion diagnostic claims. PreCheck Health Services is excited to introduce this test under the name SolidTumorCheck+, marking the beginning of a new phase in precision oncology and pa ...

SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed a ...

Illumina, Inc. (ILMN) has secured the FDA’s approval for its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and first two companion diagnostic (CDx) indications. The test analyses more than 500 genes to profile a patient's solid tumor, improving the chances of identifying an immuno-oncology or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.The latest development marks a long-awaited milestone for the company’s oncology customers and c ...

"FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community," said Everett Cunningham, chief commercial officer of Illumina. "We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more patients."A CDx test may identify whether a patient's tumor has a specific gene change or biomarker that can be targeted by a the ...

Investors in Illumina, Inc. (ILMN) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $75 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean ...

da-kukIntroduction Illumina (NASDAQ:ILMN) has finally rid itself of GRAIL. My last look at the stock followed its 2023 financial report, wherein revenues and gross margins dropped and SG&A expenses climbed. The company also projected "approximately flat" revenues in 2024. This was in the context of a valuation that was rich. My recommendation was "sell," noting that the company's "premium valuation is not justified by its current performance or future prospects." Illumina stock is -1.68% since this upda ...